Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP518 in mCRPC
NCT05252364Phase 1Completed
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of HP518 in metastatic castration-resistant prostate cancer (mCRPC) (7 arms), sponsored by Hinova Pharmaceuticals Inc. Primary endpoints: Incidences of Protocol-defined Dose Limiting Toxicity at 28 days, Incidence of Treatment-Emergent Adverse Events at 1 year and 4 more. Started Dec 2021; status: completed.
02
Drugs
HP518
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05252364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252364.